CJC-1295 DAC (5 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject twice weekly subcutaneously (e.g., Monday/Thursday or Tuesday/Friday). The extended 6 to 8 day half-life from the DAC modification supports less frequent dosing compared to non-DAC GHRH analogs. Once-weekly dosing is also studied; adjust frequency based on protocol requirements. For 10 unit (0.10 mL) or smaller administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 2.5 mg/mL, 1 unit = 0.01 mL = 25 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C; stable for 2 to 4 weeks; avoid freeze-thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on an 8 to 16 week twice-weekly protocol with gradual titration.

Peptide Vials (CJC-1295 DAC, 5 mg each):

• 8 weeks: ~3 vials (~10.2 mg total).
• 12 weeks: ~4 vials (~18.2 mg total).
• 16 weeks: ~6 vials (~26.2 mg total).

Insulin Syringes (U-100):

• Per week: 2 syringes (twice weekly).
• 8 weeks: 16. 12 weeks: 24. 16 weeks: 32.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (3 vials): 1 bottle. 12 weeks (4 vials): 1 bottle. 16 weeks (6 vials): 2 bottles.

Alcohol Swabs:

• Per week: 4 swabs (2 per injection x 2 injections).
• 16 weeks: 64 swabs (1 x 100-count box).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document each dose, injection site, and timing to maintain consistency.
• The DAC modification provides sustained release; maintain consistent twice-weekly scheduling.
• The 5 mg vial provides more doses per vial, reducing reconstitution frequency.

How This Works

CJC-1295 DAC mimics endogenous GHRH, binding to GHRH receptors on pituitary somatotrophs to drive GH release. The DAC modification (albumin-binding moiety) keeps the GHRH analog circulating for days rather than minutes, extending the half-life to approximately 6 to 8 days. The resulting GH surge stimulates IGF-1 production (primarily in the liver); IGF-1 then mediates many growth and metabolic effects through JAK/STAT signaling pathways. Notably, pulsatile GH secretion persists even during continuous CJC-1295 stimulation, preserving physiological release patterns.

Benefits & Side Effects

Observations from preclinical and clinical literature.

• Supports sustained elevation of GH and IGF-1 in a dose-dependent manner.
• May promote increased lean body mass, reduced fat mass, and improved body composition consistent

with GH/IGF-1 axis activation.

• Enhanced protein synthesis and recovery potential through anabolic signaling.
• Generally well tolerated in clinical studies; occasional mild injection-site reactions (redness, swelling)

may occur.

• Some individuals report transient flushing, headache, or water retention during initial titration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced, protein-forward diet tailored to energy and recovery needs.
• Combine resistance training and aerobic activity to reinforce GH-mediated adaptations.
• Prioritize quality sleep (7 to 9 hours) as endogenous GH release peaks during deep sleep.
• Manage stress to support hormonal balance and adherence.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Teichman SL et al. Prolonged stimulation of GH and IGF-1 by CJC-1295 in healthy adults (J Clin Endocrinol Metab, 2006).
2. Ionescu M et al. Pulsatile GH secretion persists during continuous CJC-1295 stimulation (J Clin Endocrinol Metab, 2006).
3. Alba M et al. Once-daily CJC-1295 normalizes growth in GHRH knockout mouse (Am J Physiol Endocrinol Metab, 2006).
4. Brinkman JE et al. Physiology, Growth Hormone (StatPearls, NCBI Bookshelf).